Phaseline

Targets › ADRB3

ADRB3 (Beta-3 adrenergic receptor): drug programs, companies and trials

16 programs from 16 companies in 95 trials: 37 Phase 4, 27 Phase 2, 16 Phase 1, 15 Phase 3; Neurology, Gastroenterology, Oncology; next expected readout Dec 2026.

G protein-coupled receptor for catecholamines that couples to both G(s) and G(i) proteins, leading to either activation or inhibition of adenylate cyclase and cAMP-dependent pathway, respectively. The rank order of potency for physiological agonists is norepinephrine > epinephrine. (UniProt, P13945)

Open in Phaseline: the race on ADRB3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
King's College Hospital NHS TrustCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Cirrhosis, LiverDec 2026
Hospital Sirio-LibanesCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4CancerMay 2027
Post Graduate Institute of Medical Education and Research, ChandigarhCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Cirrhotic CardiomyopathyJan 2029
Taipei Veterans General Hospital, TaiwanCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Hepatocellular Carcinoma (HCC); CirrhosisOct 2030
University of RochesterCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Heart Failure With Reduced Ejection Fraction (HFrEF)Jun 2031
Chinese University of Hong KongCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Portal HypertensionJul 2031
Bispebjerg HospitalCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 4Acute Myocardial InfarctionDec 2035
SWOG Cancer Research NetworkCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 3CardiotoxicityJun 2031
Ain Shams UniversityCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 3Cardiotoxicity–
Astellasmirabegron
Beta-3 adrenergic receptor agonist
ADRB3Phase 3Neurogenic Detrusor Overactivity; Overactive Bladder Syndrome; Effect of Drug; Urinary Bladder, Overactive …–
Urovant SciencesVibegron
Beta-3 adrenergic receptor agonist
ADRB3Phase 2Neurogenic Detrusor Overactivity; ObesityMar 2030
Sherief Abd-ElsalamCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 2Esophageal VaricesDec 2030
Michele Tagliati, MDCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 2REM Sleep Behavior Disorder–
Cedars-Sinai Medical CenterCarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 2REM Sleep Behavior Disorder–
Mansoura Universitycarvedilol
Adrenergic receptor beta antagonist; Adrenergic receptor alpha-1 antagonist
ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1DPhase 1TBI Traumatic Brain Injury–

Conditions

Nicotine Dependence (3) Cardiotoxicity (2) Psoriasis Vulgaris (2) Cytomegalovirus (CMV) (2) REM Sleep Behavior Disorder (2) Neurogenic Detrusor Overactivity (2) Urgency Urinary Incontinence (2) Urinary Incontinence in Children (2) Hepatocellular Carcinoma (HCC) (1) Cirrhosis (1) Heart Failure With Reduced Ejection Fraction (HFrEF) (1) Portal Hypertension (1)

Modalities

small molecule (16)

Companies

Taipei Veterans General Hospital, Taiwan (1) University of Rochester (1) Chinese University of Hong Kong (1) Ain Shams University (1) King's College Hospital NHS Trust (1) SWOG Cancer Research Network (1) Post Graduate Institute of Medical Education and Research, Chandigarh (1) University of California, San Francisco (1) Hospital Sirio-Libanes (1) Mansoura University (1) Michele Tagliati, MD (1) Cedars-Sinai Medical Center (1) Bispebjerg Hospital (1) Sherief Abd-Elsalam (1) Urovant Sciences (1) Astellas (1)

Related targets

ADRB2 (14) ADRB1 (13) ADRA1A (13) ADRA1D (13) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MAP2K1 (1) MAP2K2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.